Ocular surface effects of thyroid disease

Ocular Surface

Volumn 8, Issue 1, 2010, Pages 29-39

  Sokol, Jason A ^a   Foulks, Gary N ^a   Haider, Ali ^a   Nunery, William R ^a,b  

^a University of Louisville School of Medicine   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Dry eye disease; Graves' disease; Graves' ophthalmopathy; Graves' orbitopathy; Ocular surface damage; Ophthalmic graves' disease; Thyroid eye disease; Thyroid associated ophthalmopathy

Indexed keywords

CYCLOSPORIN A; IODINE 131; PREDNISONE;

CLINICAL ASSESSMENT; CLINICAL FEATURE; ENDOCRINE OPHTHALMOPATHY; EYE; EYELID REFLEX; GRAVES DISEASE; HEAT TOLERANCE; HUMAN; HYPERTHYROIDISM; INFLAMMATION; KERATOCONJUNCTIVITIS; LACRIMAL DUCT; LAGOPHTHALMOS; LUBRICATION; NONHUMAN; RADIOTHERAPY; REVIEW; RISK FACTOR; SURFACE CHARGE; TEAR FILM; THYROID DISEASE;

EID: 77649199240     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-0124(12)70215-X     Document Type: Article

References (55)

1. Khoo TK, Bahn RS. Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies. Thyroid 2007;17:1013-8
2. Kersten RC, Codere f, Dailey ra, et al. Section 7: Orbit, eyelids, and lacrimal system, in: Basic and clinical science course. San Francisco,American Academy of Ophthalmology, 2005
3. Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996;121:284-90
4. Bartley GB, Fatourechi V, Kadramas EF et al. long-term follow-up of Graves' ophthalmopathy in an incidence cohort. Ophthalmology 1996;103:958-62
5. Bartalena L, Tanda ML. Clinical Practice. Graves' ophthalmopathy. N Engl J Med 2009;360:994-1001
6. Nunery WR. Ophthalmic Graves' disease: a dual theory of pathogenesis. Ophthalmol Clin North Am 1991;4:73-87
7. Nunery WR, Martin RT, Heinz GW, Gavin TJ. The association of cigarette smoking with clinical subtypes of ophthalmic Graves' disease. Ophthal Plast Reconstr Surg 1993;9:77-82.
8. Nunery WR, Nunery CW, Martin RT, et al. The risk of diplopia following orbital floor and medial wall decompression in subtypes of ophthalmic Graves' disease. Ophthal Plast Reconstr Surg 1997;13:153-60
9. Hiromatsu Y, Kaku H, Miyake I, et al. role of cytokines in the pathogenesis of thyroid-associated ophthalmopathy. Thyroid 2002;12:217-21
10. Hiromatsu Y, Yang D, Bednarczuk T, et al. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2000;85:1194-9
11. Dutton JJ, Haik BG. Thyroid eye disease: diagnosis and treatment. new york, Marcel Dekker, 2002
12. Prummel WF, Wiersinga WM. Smoking and risk of Graves' disease. JaMa 1993;269:;518-9
13. Lois N, Abdelkader E, Reglitz K, et al. Environmental tobacco smoke exposure and eye disease. Br J Ophthalmol 2008;92:1304-10
14. Perros P, Neoh C, Dickinson J. Thyroid eye disease. BMJ 2009;338: b560
15. Gupta A, Sadeghi PB, Akpek EK. Occult thyroid eye disease in patients presenting with dry eye symptoms. Am J Ophthalmol 2009;147:919-23
16. Schaumberg DA, Sullivan DA, Buning JE et al. Prevalence of dry eye syndrome among uS women. Am J Ophthalmol 2003;136:318-26
17. Coulter I, Frewin S, Krassas GE, et al. Psychological implications of Graves' orbitopathy. Eur J Endocrinol 2007;157:127-31
18. Rootman J, Dolman PJ. Thyroid orbitopathy, in: Rootman J. Disease of the orbit. Philadelphia, lippincott Williams & Wilkins, 2003, ed 23, pp169-212
19. Mcculley JP, Moore MB, Matoba AY. Mucus fishing syndrome. Ophthalmology 1985;92:1262-5
20. Gilbard JP, Farris RL. Ocular surface drying and tear film osmolarity in thyroid eye disease. Acta Ophthalmol 1983;61:108-116
21. Brasil MV, Brasil OF, Vieira RP, et al. [Tear film analysis and its relation with palpebral fissure height and exophthalmos in Graves' ophthalmopathy]. Arq Bras Oftalmol 2005;68:615-8
22. (No authors listed.) The definition and classification of dry eye disease. report of Definition and classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:75-92
23. Iskeleli G, Karakoc Y, Abdula a. Tear film osmolarity in patients with thyroid ophthalmopathy. Jpn J Ophthalmol 2008;52:323-6
24. Eckstein AK, Finkenrath A, Heiligenhaus A, et al. Dry eye syndrome in thyroid-associated ophthalmopathy: lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies. Acta Ophthalmol Scand 2004;82(3 Pt 1):291-7
25. Theodore FH. Superior limbic keratoconjunctivitis. Eye Ear Nose Throat Month 1963;42:25-8
26. Passons GA, Wood TO. conjunctival resection for superior limbic keratoconjunctivitis. Ophthalmology 1984;91:966-8
27. Kadrmas EF, Bartley GB. Superior limbic keratoconjunctivitis. a prognostic sign for severe Graves' ophthalmopathy. Ophthalmology 1995;102:1472-5
28. Frueh BR, Garber FW, Musch DC. The effects of Graves' eye disease on levator muscle function. Ophthalmic Surg 1986;17:142-5
29. (No authors listed). Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:108-52
30. Yildiz EH, Fan VC, Banday H, et al. evaluation of a new tear osmometer for repeatability and accuracy, using 0.5-microl (500-nanoliter) samples. Cornea 2009;28:677-80
31. Tallstedt L, Lundell G, TØrring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992;326:1733-8
32. Nunery WR: Ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992;327:1320-1
33. Murube J, Paterson A, Murube E. Classification of artificial tears. I: composition and properties. Adv Exp Med Biol 1998;438:693-704
34. Ousler GW, Michaelson C, Christensen MT:An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops. Cornea 2007 ;26:949-52
35. Korb DR, Scaffidi RC, Greiner JV, et al. The effect of two novel lubricant eye drops on tear film lipid layer thickness in subjects with dry eye symptoms. Optom Vis Sci 2005;82:594-601
36. Christensen MT. Corneal staining reductions observed after treatment with Systane® lubricant eye drops. Adv Ther 2008;25:1191-9
37. Holly FJ, Lamberts DW. Effect of nonisotonic solutions on tear film osmolality. Invest Ophthalmol Vis Sci 1981;20:236-45
38. Yancey PH: Organic osmolytes as compatible, metabolic and counteracting cryoprotectants in high osmolarity and other stresses. J Exp Biol 2005;208:2819-30
39. Corrales RM, Luo L, Chang EY, Pflugfelder SC. Effects of osmoprotectants on hyperosmolar stress in cultured human corneal epithelial cells. Cornea 2008;27:574-9
40. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107:631-9
41. Kabat AG. Lacrimal occlusion therapy for the treatment of superior limbic keratoconjunctivitis. Optom Vis Sci 1998;75:714-8
42. Goldberg RA. Advances in surgical rehabilitation in thyroid eye disease. Thyroid 2008;18:989-95
43. Gorman CA, Garrity JA, Fatourechi V, et al. a prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001;108:1523-34
44. Kazim M. Perspective - Part II. radiotherapy for Graves The Ocular Surface / January 2010, VOl. 8, nO. 1 / www.theocularsurface.com 39 orbitopathy: the columbia university experience. Ophthal Plast Reconstr Surg 2002;18:173-4
45. Parsons JT, Bova FJ, Fitzgerald CR, et al. Severe dry-eye syndrome following external beam irradiation. Int J Radiat Oncol Biol Phys 1994;30:775-80
46. Gorman CA, Garrity JA,Ffatourechi V, et al. A prospective, randomized, double- blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001;108:1523-34
47. Mouritis MP, van Kempen-Harvteveld ML, Garcia MB, et al. Radiotherapy for Graves' orbitopathy: randomized placebo-controlled study. Lancet 2000;355:1505-9
48. Wakelkamp IM,Tan H, Saeed P, et al. Orbital irradiation for Graves' ophthalmopathy: Is it safe? a long-term follow-up study. Ophthalmology 2004;111:1557-62
49. Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989;321:1353-9
50. Bordaberry M, Marques DL, Pereira-Lima JC, et al. Repeated peribulbar injections of triamcinolone acetonide: a successful and safe treatment for moderate to severe Graves' ophthalmopathy. Acta Ophthalmol 2009;87:58-64
51. El fassi D, Nielsen HC, Hasselbalch HC, Heged̈s L. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 2006;16:709-10
52. Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007;156:33-40
53. Paridaens D, van den Bosch WA, van der Loos TL, et al. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 2005;19:286-9
54. Glinoer D, Etienne-Decerf J, Schrooyen M, et al. Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy. Metab Pediatr Syst Ophthalmol 1988;11:133-40
55. Lauer SA, Silkiss RZ, McCormick SA. Oral montelukast and cetirizine for thyroid eye disease. Ophthal Plast Reconstr Surg 2008;24:257-61